Results 111 to 120 of about 692,269 (276)

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.

, 2013
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth leading cause of cancer death in the western world, with a 5-year survival rate below 5%.
Conradt, Laura;Henrich, Annika;Wirth, Matthias;Reichert, Maximilian;Lesina, Marina;Algül, Hana;Schmid, Roland M;Krämer, Oliver H;Saur, Dieter;Schneider, Günter
core   +1 more source

Multicomponent reactions for DNA‐encoded library construction: Scaffold diversity and reaction engineering strategies

Bulletin of the Korean Chemical Society, EarlyView.
Abstract DNA‐encoded libraries (DELs) enable large‐scale screening for hit identification, but accessing sp3‐rich, three‐dimensional chemotypes beyond flat, aromatic scaffolds remains challenging. Multicomponent reactions (MCRs) assemble such complexity from simple building blocks in a single step, and reaction‐engineering strategies have extended on ...
Jimin Moon, Hyemin Yoon, Kang Ju Lee, Hyun Jin Kim   +3 more
wiley   +1 more source

Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy

The interaction between murine double minute (MDM2) and p53 is a major target in anticancer drug design. Several potent compound series, including the nutlins and spirooxindoles, have previously been established as high-affinity antagonists of MDM2.
Noble ME, Wright DJ, McDonnell JM, Riedinger C, Mulks F, Endicott JA, Hardcastle I   +6 more
core   +3 more sources

Clinical overview of MDM2/X targeted therapies

Frontiers in Oncology, 2016
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions, maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation, and inhibiting its transcriptional activity.
Andrew eBurgess, Andrew eBurgess, Kee Ming Chia, Sue eHaupt, David eThomas, David eThomas, Ygal eHaupt, Elgene eLim, Elgene eLim   +8 more
doaj   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

MDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets

BMC Cancer
Background A complete response following neoadjuvant therapy occurs only in a fraction of patients with esophageal adenocarcinoma (EAC). Further targeted treatment options are needed to improve treatment response and patient survival. Mouse double minute
Karl Knipper, Christiane J. Bruns, Felix C. Popp, Thomas Schmidt, Bastian Grothey, Alexander Quaas, Su Ir Lyu   +6 more
doaj   +1 more source

The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies

Pharmaceuticals
Osteosarcoma, the most prevalent primary malignant bone tumor in children and adolescents, is characterized by high rates of metastasis, recurrence, and chemotherapy resistance, leading to suboptimal patient survival. The MDM2-p53 pathway plays a pivotal
Wenxia Deng, Songyan Gao, Lige Yan, Qiuju Su, Si Chen   +4 more
doaj   +1 more source

Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

, 2015
Anaïs Pujals,1–3,* Loëtitia Favre,4,* Philippe Gaulard,1–3 Joëlle Wiels41Department of Pathology, Assistance Publique-Hôpitaux de Paris, CHU Henri Mondor, 2Faculté de Médecine, Université Paris-Est Cr&
Favre L, Pujals A, Wiels J, Gaulard P
core  

Ordering of the N‑Terminus of Human MDM2 by Small Molecule Inhibitors

, 2016
Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new
Paul D. Schnier (1592263), Yosup Rew (1698184), Xin Huang (11077), Jing Zhou (168494), Peter Yakowec (1698136), Leszek Poppe (559005), Evelyn Yang (2033641), Jeffrey Lewis (559008), Alexander M. Long (1656211), Klaus Michelsen (1261590), John B. Jordan (1592266)   +10 more
core   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source